| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 1, 2025 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/25/2025 | $31.00 | Buy | Guggenheim |
| 9/20/2024 | $2.00 → $35.00 | Hold → Buy | Jefferies |
| 9/13/2021 | $3.50 | Neutral | HC Wainwright & Co. |
| 9/2/2021 | Outperform → Market Perform | William Blair |
EFFECT - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
S-3 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
10-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – – Interim Phase 1b proof-of-concept data, including initial efficacy measures, anticipated in fall 2025 for ABI-5366 and ABI-1179, long-acting helicase-primase inhibitor candidates for recurrent genital herpes – SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the year ended December 31, 2024, and recent highlights. "We are well-positioned to deliver important clinic
– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures – SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1a trial of ABI-6250, the company's orally bioavailable, small molecule hepatitis delta virus (HDV) entry inhibitor candidate. This Phase 1a study w
– ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose – – Assembly Bio to move ABI-1179 directly into Phase 1b portion of the ongoing Phase 1a/b study in participants with recurrent genital herpes – – Phase 1b to run concurrently with ongoing Phase 1b study for ABI-5366, with interim data for both candidates anticipated in fall 2025 – SOUTH SAN FRANCISCO, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announce
-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C vi
−ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-enabling studies for its long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program. 5366 is the first development candidate from Assembly Bio's discovery pipeline nominated for adv
Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. "I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board," said Dr. Walter Strapps, co-founder and CEO of Carver. "Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic." Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founde
Guggenheim initiated coverage of Assembly Biosciences with a rating of Buy and set a new price target of $31.00
Jefferies upgraded Assembly Biosciences from Hold to Buy and set a new price target of $35.00 from $2.00 previously
HC Wainwright & Co. initiated coverage of Assembly Biosciences with a rating of Neutral and set a new price target of $3.50
SC 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)